Green Therapeutic Biocapsules: Using Plant Cells to Orally Deliver Biopharmaceuticals
Review
-
- Overview
-
- Research
-
- Identity
-
- Additional Document Info
-
- View All
-
Overview
abstract
-
The use of innovative platforms to produce biopharmaceuticals cheaply and deliver them through noninvasive routes could expand their social benefits. Coverage should increase as a consequence of lower cost and higher patient compliance due to painless administration. For more than two decades of research, oral therapies that rely on genetically engineered plants for the production of biopharmaceuticals have been explored to treat or prevent high-impact diseases. Recent reports on the successful oral delivery of plant-made biopharmaceuticals raise new hopes for the field. Several candidates have shown protection in animal models, and efforts to establish their production on an industrial scale are ongoing. These advances and perspectives for the field are analyzed. © 2018 Elsevier Ltd
publication date
funding provided via
published in
Research
keywords
-
cell wall; glucocerebrosidase; immunotherapy; low-cost therapies; oral delivery; plant-based vaccines Biotechnology; Cell walls; Glucocerebrosidase; immunotherapy; Low costs; Oral delivery; Disease control; angiotensin converting enzyme 2; angiotensin[1-7]; blood clotting factor 8; blood clotting factor 9; cholera toxin B subunit; DNA vaccine; Escherichia coli vaccine; etanercept; exendin 4; fusion protein; glucosylceramidase; hepatitis C vaccine; Human immunodeficiency virus antibody; influenza vaccine; measles vaccine; monoclonal antibody; myelin basic protein; poliomyelitis vaccine; pollen antigen; proinsulin; prx 106; recombinant glucan 1,4 alpha glucosidase; taliglucerase alfa; unclassified drug; vaccine; biological product; Alzheimer disease; antiinflammatory activity; colitis; drug delivery system; drug effect; drug synthesis; encapsulation; Escherichia coli infection; genetic engineering; glycogen storage disease type 2; hemophilia A; hemophilia B; hepatitis; immunogenicity; immunomodulation; immunotherapy; insulin dependent diabetes mellitus; molecular farming; Nicotiana tabacum; non insulin dependent diabetes mellitus; nonhuman; plant cell; pollen allergy; priority journal; pulmonary hypertension; Review; uveoretinitis; vaccination; vaccine production; human; metabolism; oral drug administration; plant cell; transgenic plant; Administration, Oral; Biological Products; Drug Delivery Systems; Humans; Plant Cells; Plants, Genetically Modified
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional Document Info
start page
end page
volume
issue